EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Medication Growth Following Diagnosis of Intellectual and Developmental Disabilities at Varying Ages Throughout Childhood

Robert B Christian, Izabela E Annis, Neal A deJong iD, Scott A Davis iD, Phillip M Hughes iD, Kathleen C Thomas iD

Pharmacoepidemiology and Drug Safety · 2026-09 · 35 (9)

DOI: 10.1002/pds.70456 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 17.08.2026. Verfasst von Robert B Christian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Developmental Disabilities, Intellectual Disability, Polypharmacy, Psychotropic Drugs. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AHRQ HHS, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Agency for Healthcare Research and Quality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To characterize age‐related trajectories in psychotropic medication and polypharmacy use among children newly diagnosed with intellectual and developmental disabilities (IDD), addressing an evidence gap in longitudinal prescribing patterns.

Methods

This study uses a retrospective longitudinal cohort design and commercial insurance claims from the southeast (2011–2021) to study children newly diagnosed with IDD, aged 2–17 years ( N = 938). Psychotropic medication use was defined as ≥ 1 prescription fill per year; polypharmacy as ≥ 2 classes used concurrently for ≥ 60 days. Generalized linear mixed models with natural cubic splines describe longitudinal growth trajectories as a function of age at first IDD diagnosis and follow‐up year, adjusting for gender, cohort year and region of residence.

Results

Within 3 years of diagnosis, 40.1% of children initiated psychotropic medication, and 9.4% experienced sustained polypharmacy. Medication use increased with each follow‐up year among children diagnosed before age 12. For example, children diagnosed at age 2 had a 2.34‐fold increase in medication use by year 3 versus year 1 (95% CI: 1.56–3.53) and nearly a sixfold increase in polypharmacy (OR = 5.89; 95% CI: 2.89–11.99). In contrast, children diagnosed during adolescence showed higher initial use but minimal growth. Psychiatric comorbidities also increased with time, particularly among younger children.

Conclusion

Children diagnosed with IDD at younger ages experience steep increases in psychotropic medication use over time, including sustained exposure to polypharmacy. Additional research on long‐term benefits and harms of psychiatric medication use is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Developmental DisabilitiesIntellectual DisabilityPolypharmacyPsychotropic DrugsPractice Patterns, Physicians'HumansChildChild, PreschoolAdolescentLongitudinal StudiesRetrospective StudiesMaleFemaleAge Factors

Stichwörter der Autor:innen

children and adolescentsintellectual and developmental disorderspediatric psychopharmacologypsychopharmacology and polypharmacy trends

Substanzen

Psychotropic Drugs

Autor:innen und Institutionen

  • Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
  • University of North Carolina at Chapel Hill Cecil G Sheps Center for Health Services Research, Chapel Hill, North Carolina, USA.
  • Department of Pharmaceutical Sciences, Binghamton University State University of New York, Binghamton, New York, USA.

ORCID-Profile: Neal A deJong, Scott A Davis, Phillip M Hughes, Kathleen C Thomas

Förderung

  • AHRQ HHS
  • UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
  • Agency for Healthcare Research and Quality

Zitieren

APA

Christian, R. B., Annis, I. E., deJong, N. A., Davis, S. A., Hughes, P. M., & Thomas, K. C. (2026). Medication Growth Following Diagnosis of Intellectual and Developmental Disabilities at Varying Ages Throughout Childhood. Pharmacoepidemiology and Drug Safety, 35(9). https://doi.org/10.1002/pds.70456

Vancouver

Christian RB, Annis IE, deJong NA, Davis SA, Hughes PM, Thomas KC. Medication Growth Following Diagnosis of Intellectual and Developmental Disabilities at Varying Ages Throughout Childhood. Pharmacoepidemiology and Drug Safety. 2026;35(9). doi:10.1002/pds.70456

BibTeX
@article{Christian2026,
  author = {Christian, Robert B and Annis, Izabela E and deJong, Neal A and Davis, Scott A and Hughes, Phillip M and Thomas, Kathleen C},
  title = {Medication Growth Following Diagnosis of Intellectual and Developmental Disabilities at Varying Ages Throughout Childhood},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  volume = {35},
  number = {9},
  doi = {10.1002/pds.70456}
}
Kostenlos starten →